A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
This systematic review evaluates the cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in adults with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease, chronic kidney disease, or hea…
AIM: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes, chronic weight management and obstructive sleep apnoea (in the US). To assess the contribution of…
Discourse around the usage of weight-loss drugs (semaglutide, GLP-1 agonists, Ozempic, Wegovy) center around how people are precluded from access, a phenomenon understood as stratified biomedicalization. However, this research project finds people re…
BACKGROUND: Prior studies showed worse outcomes in obese inflammatory bowel disease (IBD) patients, especially those related to hospitalizations, surgery, and steroid-free remission. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstra…
: Semaglutide is a Glucagon-like peptide-1 receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM) and weight management. While its clinical benefits are well established, concerns have emerged over off-label use, underrep…
INTRODUCTION: Oral semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) approved for improving glycemic control in adults with type 2 diabetes (T2D). The PIONEER REAL program evaluates clinical and patient-reported outcomes of oral sem…
BACKGROUND: Managing severe obesity in youth with chronic, progressive conditions, such as juvenile Huntington disease, presents unique challenges. Juvenile Huntington disease, is characterized by rapid neurodegeneration, with most patients experienc…
Metabolic dysfunction-associated steatohepatitis (MASH), the progressive inflammatory form of MASLD, is now a leading cause of chronic liver disease worldwide. Driven by obesity and type 2 diabetes, MASH significantly increases the risk of cirrhosis,…
INTRODUCTION: IcoSema is under development as a once-weekly injectable combination therapy of icodec (basal insulin) and semaglutide (glucagon-like peptide 1 receptor agonist). This study assessed the pharmacokinetic characteristics of icodec and sem…
BACKGROUND: IcoSema is a once‑weekly combination therapy of basal insulin icodec (icodec) and semaglutide (a GLP‑1 analogue) currently in development. COMBINE 1 compared the efficacy and safety of IcoSema with once‑weekly icodec alone in adults with…
Sjögren's syndrome is a chronic autoimmune disorder with limited therapeutic options. Glucagon-like peptide-1 (GLP-1) receptor agonists, primarily used for diabetes and obesity, have emerging evidence of anti-inflammatory and immunomodulatory effects…
OBJECTIVE: To encourage continued research of the delayed gastric emptying effect of glucagon-like peptide-1 receptor agonists and its effect on absorption of orally administered estrogen. METHODS: A case is reported of a 51-year-old postmenopausal f…
BACKGROUND: Semaglutide 2.4 mg benefits weight loss and reduction of cardiovascular disease (CVD) risk factors in adults with obesity. We estimated the US population eligibility for semaglutide 2.4 mg (based on the weight management indication) and t…
OBJECTIVE: This systematic review aimed to assess the efficacy and safety of GLP-1 RAs in adults with obesity or overweight, by comparing different GLP-1 RAs, identifying the most effective agents, and evaluating adverse effects. METHODS: We systemat…